Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cell and Gene Therapy Contract Research Organization Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec Scale Integrated Trials

globenewswire.com
TMO Mentioned as a key player in the cell and gene therapy CRO market, suggesting its involvement in the growing industry but without specific positive or negative performance indicators. IQV Listed as a major player in the cell and gene therapy CRO market, indicating its participation in a growing sector, but without specific performance details. ICLR Mentioned as a key player in the cell and gene therapy CRO market, indicating its presence in a growing industry, but without specific performance details.

Cell and Gene Therapy Contract Research Organization Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec Scale Integrated Trials Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Cell and Gene Therapy Contract Research Organization Market Report 2026" has been added to ResearchAndMarkets.com's offering.

Cell and Gene Therapy Contract Research Organization Market to Reach $12.36 Billion by 2030

The global cell and gene therapy contract research organization market is experiencing rapid expansion as biotechnology and pharmaceutical companies increasingly outsource specialized research and development activities. The market is projected to grow from $6.92 billion in 2025 to $7.76 billion in 2026, representing a compound annual growth rate (CAGR) of 12.1%.

Historic market growth has been supported by the rising number of early-stage cell and gene therapy programs, limited in-house development capabilities among therapy sponsors, expanding rare disease research pipelines, and the growing regulatory complexity associated with advanced therapies. Increased reliance on external scientific, clinical, and regulatory expertise has also strengthened demand for specialized contract research services.

The cell and gene therapy CRO market is forecast to reach $12.36 billion by 2030, expanding at a CAGR of 12.3%. Key growth drivers include increasing clinical trial activity in gene therapy, greater investment in oncology and genetic disorder research, expansion of personalized medicine programs, and demand for faster development timelines. Collaboration between biotechnology companies and CROs is also expected to increase as sponsors seek access to specialized infrastructure, scientific expertise, and global clinical trial capabilities.

Major cell and gene therapy contract research organization market trends include increased outsourcing of research programs and rising demand for integrated preclinical and clinical services. CROs are also expanding regulatory and compliance capabilities, vector development and manufacturing support, bioanalytical testing, biomarker services, and data-driven clinical trial management. These capabilities are becoming increasingly important as therapy developers navigate complex protocols, specialized patient recruitment requirements, and evolving regulatory standards.

Personalized medicine and targeted therapeutics are significant contributors to market growth. Regulators and healthcare systems are prioritizing precision-based treatments designed around genetic, molecular, and cellular characteristics, particularly for complex diseases with limited therapeutic options. Cell and gene therapy CROs support these programs through specialized preclinical studies, clinical trial management, regulatory strategy, safety monitoring, quality management, and analytical testing.

According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 18 personalized medicines in 2024. These products accounted for approximately 38% of all newly approved therapeutic molecular entities, highlighting the growing role of precision-based treatment development in the pharmaceutical and biotechnology sectors.

Laboratory expansion and advanced analytical services are emerging as important areas of investment. In August 2025, Labcorp Holdings Inc. expanded its cell and gene therapy laboratory in Madison, Wisconsin. The expanded facility strengthened capabilities in cell characterization, vector analytics, regulatory-compliant testing, high-throughput sample processing, and complex cell and gene therapy workflows. Such investments are intended to improve research precision, accelerate development, and support regulatory submissions.

Strategic acquisitions are also reshaping the competitive environment. In January 2023, Novotech Clinical Research acquired EastHORN Clinical Services for an undisclosed amount. The acquisition expanded Novotech's clinical, medical, and regulatory expertise across Europe, supporting the delivery of early- through late-phase clinical development services for biotechnology clients. It also enhanced the organization's ability to manage global clinical trial programs involving advanced cell and gene therapies.

The market supports a broad range of therapeutic areas, including oncology, central nervous system disorders, infectious diseases, immunological conditions, cardiovascular diseases, respiratory diseases, diabetes, ophthalmology, and pain management. Services span project and clinical trial management, regulatory strategy, clinical monitoring, medical writing, data management, biostatistics, safety monitoring, patient recruitment, site recruitment, technology transfer, and good manufacturing practice compliance.

Tariffs are creating additional challenges for the cell and gene therapy CRO market by increasing the cost of imported laboratory instruments, bioreactors, viral vector components, analytical equipment, and research consumables. North America and Europe face notable exposure due to their reliance on imported high-end research technologies, while Asia-Pacific is experiencing cost pressure as CRO capacity expands. Although tariffs are raising operating expenses and sponsor project costs, they are also encouraging localized laboratory development, regional capacity building, and investment in domestic advanced therapy research infrastructure.

Markets Covered:

1) By Type: Preclinical Contract Research Organization; Clinical Stage Contract Research Organization; Other Types

2) By Service: Project and Clinical Trial Management; Regulatory Strategy; Data Management and Medical Writing; Clinical Monitoring; Quality Management and Good Manufacturing Practice Compliance; Biostatistics and Safety Monitoring; Patient and Site Recruitment; Technology Transfer; Other Services

3) By Indication: Oncology; Central Nervous System Disorders; Infectious Diseases; Immunological Disorders; Cardiovascular Diseases; Respiratory Diseases; Diabetes; Ophthalmology; Pain Management; Other Indications

4) By Modality: Cell-Based Therapies; Gene Therapies; Gene-Modified Cell Therapies

5) By Application: Hospital; Research Institute; Other Applications

Subsegments:

1) By Preclinical Contract Research Organization: In Vitro Testing Services; In Vivo Animal Model Services; Toxicology and Safety Assessment; Other Preclinical Services

2) By Clinical Stage Contract Research Organization: Phase I Clinical Trial Services; Phase II Clinical Trial Services; Phase III Clinical Trial Services; Other Clinical Stage Services

3) By Other Types: Regulatory Consulting Services; Process Development Services; Manufacturing Support Services; Other Support Services

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Companies Featured

The companies featured in this Cell and Gene Therapy Contract Research Organization market report include:

For more information about this report visit https://www.researchandmarkets.com/r/ta5mfg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.